Iovance Biotherapeutics (Mfg)
Philadelphia, PA
In-house manufacturer
31 confirmed programs
· 12 sponsors
· Last scored 2026-10-29
65.9
Signal Score
○ FDA Inspections
✓ Clinical Trials (31)
✓ SEC Filings (20)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Iovance Biotherapeutics (Mfg)
- Signal Score
- 65.9/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Philadelphia, PA
- Modalities
- Cell Therapy
- Active Programs
- 31 confirmed from ClinicalTrials.gov across 12 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Iovance Biotherapeutics (Mfg)
CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
74.5
31 active programs across 12 sponsors
Modalities: Cell Therapy
20 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
31 active programs across 12 sponsors · Modalities: Cell Therapy · 20 programs in advanced phases (Phase 2/3)
Programs
31
Sponsors12
ModalitiesCell Therapy
31 active programs across 12 sponsors
Modalities: Cell Therapy
20 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07288203
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in...
PHASE2
Active Not Recruiting
NCT06940739
A Study to Investigate the Safety and Efficacy of IOV-3001 in...
PHASE1/PHASE2
Recruiting
View all 31 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
68.0
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Capacity
53.0
1 manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Philadelphia, PA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Clinical Activity 31 studies
NCT07700121
PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
EARLY_PHASE1
Not Yet Recruiting
NCT07741877
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Not Yet Recruiting
NCT07192900
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
PHASE1
Recruiting
NCT07288073
TIL Therapy in cSCC and MCC
PHASE2
Recruiting
NCT07288203
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Active Not Recruiting
NCT05639972
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally...
PHASE1/PHASE2
Recruiting
NCT06940739
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With...
PHASE1/PHASE2
Recruiting
NCT06481592
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With...
PHASE2
Recruiting
NCT06151847
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion...
PHASE2
Completed
NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With...
PHASE3
Recruiting
NCT05686226
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
PHASE2
Recruiting
NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma,...
PHASE1
Recruiting
NCT05483491
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
PHASE1
Recruiting
NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in...
PHASE1/PHASE2
Recruiting
NCT05176470
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for...
PHASE1
Active Not Recruiting
NCT04614103
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
PHASE2
Recruiting
NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of...
PHASE1
Completed
NCT04111510
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated...
PHASE2
Completed
NCT04052334
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent...
PHASE1
Completed
NCT03935347
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in...
PHASE2
Withdrawn
+ 11 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity 9 open roles Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
9
open roles
6
in manufacturing, quality, PD/MSAT, engineering or regulatory (67%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 29 taken down.
By function
By site
Philadelphia, PA
profile site
3 mfg/ops · 1 QA/QC · 1 eng. · 1 other 6
3 mfg/ops · 1 QA/QC · 1 eng. · 1 other 6
iCTC
· 1 PD/MSAT · 1 other 2
· 1 PD/MSAT · 1 other 2
Tampa, FL/ ICTC Philadelphia, PA / Hybrid
· 1 other 1
· 1 other 1
Latest postings
Vice President, Research
Other (finance, HR, IT, other) · Tampa, FL/ ICTC Philadelphia, PA / Hybrid · posted Nov 18, 2026
AI Strategist, Technical Operations & Finance
Process development & MSAT · iCTC · posted Nov 16, 2026
Logistics & Planning Associate II
Manufacturing & operations · Philadelphia · posted Nov 2, 2026
Manager, Quality Assurance Operations
Quality (QA / QC) · Philadelphia, Pennsylvania · posted Oct 29, 2026
Aseptic Manufacturing Technician I - Night Shift B [Contract to Hire]
Manufacturing & operations · Philadelphia, PA · posted Jun 23, 2026
Aseptic Manufacturing Technician I - Day Shift B [Contract to Hire]
Manufacturing & operations · Philadelphia, PA · posted Jul 31, 2026
Instrumentation & Equipment Specialist II (3rd Shift Sunday - Wednesday, 10:00pm - 8:30am)
Engineering & facilities · Philadelphia, Pennsylvania · posted Sep 24, 2026
Senior Project Manager
Commercial, BD & client projects · Philadelphia, PA · posted Aug 27, 2026
Senior Manager, Cost Accounting
Other (finance, HR, IT, other) · iCTC · posted Aug 20, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Iovance Cell Therapy Center (iCTC), Philadelphia only; the rest of the board is the biotech's R&D, commercial and remote roles). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
job-boards.greenhouse.io
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Financial Intelligence
"Item 8.01 Other Events: On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press"
"The Company was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (“NCI”)."
"The Company’s multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients into a commercially viable treatment that is accessible for thousands of cancer patients."
"Amtagvi
®
is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced melanoma, defined as unresectable or metastatic melanoma, approved for use in the U.S., Canada, and Australia."
"Item 2.02 ,: including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities"
"The Company was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (“NCI”)."
"The Company’s multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients."
"Amtagvi
®
is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma, approved for use in the U.S."
"
Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI."
"Our multi-center trials, scalable manufacturing, regulatory approvals and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients."
"
Amtagvi
®
is the first one-time, individualized T cell therapy for a solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi
®
(lifileucel), the first product within our autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2, or IL-2, product used in the Amtagvi
®
treatment regimen and in other applications."
"Amtagvi
®
is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"Iovance was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute, or the NCI."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, while also marketing Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive U.S."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic research centers, including the National Cancer Institute (“NCI”)."
"launch of Amtagvi™ (lifileucel), the first product within its autologous TIL cell therapy platform, and Proleukin
®
(aldesleukin), an interleukin-2 (“IL-2”) product used in the Amtagvi™ treatment regimen."
"Amtagvi™ is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer."
"The Company was founded to build upon the promise of TIL cell therapy that was previously demonstrated in single-center clinical trials at academic centers, including the National Cancer Institute (“NCI”)."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Frequently Asked Questions About Iovance Biotherapeutics (Mfg)
How many clinical programs is Iovance Biotherapeutics (Mfg) linked to?
Iovance Biotherapeutics (Mfg) is associated with 31 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Iovance Biotherapeutics (Mfg)'s CDMO Signal Score?
Iovance Biotherapeutics (Mfg) has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Iovance Biotherapeutics (Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Iovance Biotherapeutics (Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.6
mRNA, Gene Therapy, Cell Therapy, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Compare Iovance Biotherapeutics (Mfg) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.